Academic Perspectives: Patient Populations for Frontline Luspatercept in LR-MDS
Panelists discuss how the final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024) highlights the role of luspatercept in first-line treatment for lower-risk myelodysplastic syndrome (LR-MDS), with particular consideration of ribosomal stress (RS) status and serum erythropoietin (EPO) levels, emphasizing its potential to improve hemoglobin levels and transfusion independence in this patient population.
- Discuss final efficacy and safety analysis from the COMMANDS trial (Della Porta et al, Lancet 2024).
- Elaborate on the role of luspatercept in first-line treatment of patients with LR-MDS
- Consider RS status and serum EPO level.
- What are your thoughts on the efficacy and potential benefits of luspatercept in this patient population?
Managing HER2+ Early Breast Cancer: Insights and Future Horizons
November 28th 2023Sandra M. Swain, MD, FACP, FASCO, discusses the potential role for HER2-directed TKIs for the treatment of patients with early-stage HER2+ breast cancer and shares insights about emerging data that could impact the future treatment landscape.
Read More
